What are the considerations for the pharmacotherapeutic management of acute promyelocytic leukemia in children?

Expert Opin Pharmacother. 2022 Feb;23(3):289-294. doi: 10.1080/14656566.2021.2006182. Epub 2021 Nov 28.

Authors

Carmelo Gurnari^{1

2}, Mariadomenica Divona³, Maria Teresa Voso^{1

4}

Affiliations

¹ Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
² Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, OH, USA.
³ Laboratory of Advanced Diagnostics in Oncohematology, Hematology Department, Tor Vergata Hospital, Rome, Italy.
⁴ Department of Neuro-Oncohematology, Rome, Italy.

PMID: 34842028
DOI: 10.1080/14656566.2021.2006182

No abstract available

Keywords: Arsenic trioxide; all-trans retinoic acid; chemotherapy-free regimens; long-term sequelae; pediatric patients; tailored treatment.

Publication types

Editorial

MeSH terms

Antineoplastic Agents* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Child
Humans
Leukemia, Promyelocytic, Acute* / drug therapy

Substances

Antineoplastic Agents